Back to Search
Start Over
959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
- Publication Year :
- 2021
- Publisher :
- BMJ Publishing Group, 2021.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 9
- Issue :
- Suppl 2
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.bc94a9e9c64e462b8ba5414a6783526f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2021-SITC2021.959